Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Beth Israel Deaconess Medical Center
- Study ID
- NCT03782064
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — DRUGNivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
- DC/myeloma fusions/GM-CSF — BIOLOGICALThe DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
Study Details
This research study is studying a cancer vaccine called Dendritic Cell/MM Fusion vaccine (DC/MM vaccine) in combination with nivolumab, as a possible treatment for multiple myeloma (MM). The drugs involved in this study are: * Dendritic Cell/MM Fusion vaccine (DC/MM vaccine) * Nivolumab, an immunotherapy drug
Key Dates
- Start date
- Feb 22, 2019
- Status verified
- Jun 2023
- Primary completion
- Jan 31, 2021
- Completion
- Jan 31, 2021
Study Design
- Enrollment
- 5 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Nivolumab+DC/myeloma fusions/GM-CSF* Nivolumab will be given every two weeks * The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle
Primary Outcome Measure
Number of Patients Who Develop Immunologic Response to Nivolumab and the DC/MM Fusion Vaccine [ Time Frame: 2 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | - |
Find similar trials in Boston, MA
By condition
By specialty
By research site
Related Studies
- Collection of Samples and Clinical Data From Patients With Amyloid DiseasesRecruiting · Boston Medical Center · Boston, Massachusetts
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)Recruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.PHASE1 · Recruiting · Newave Pharmaceutical Inc · Chicago, Illinois